True innovation takes time and an unwavering commitment to change the lives of patients and caregivers impacted by cancer. At NewLink Genetics we will stop at nothing to bring new immuno-oncology treatments to those who need them by relentlessly pursuing innovation and medical inspiration.
NewLink Genetics’ immuno-oncology portfolio candidates are poised to change the oncology landscape. Our pipeline includes clinical candidates designed to harness multiple components of the immune system to combat a wide range of cancers.
Much of the focus in our research and development is on indoleamine 2,3-dioxygenase (IDO). IDO is an increasingly important and validated immuno-oncology target.
Our lead programs consist of two differentiated product candidates that target the IDO pathway. Indoximod is the most advanced with multiple trials across various cancer indications. NLG802, which is a prodrug of indoximod, entered the clinic in 2017. These product candidates have independent clinical development paths with the potential to enhance the outcomes for patients when used in combination with anti-PD-1 agents, cancer vaccines, chemotherapy or other anticancer therapies.
Indoximod and NLG802 share a differentiated mechanism of action distinct from other drugs in this class, which focus exclusively on enzymatic inhibition, and reverse immunosuppression within the IDO pathway.